Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
11 hedge funds and large institutions have $875K invested in Plus Therapeutics in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
120% more funds holding
Funds holding: 5 → 11 (+6)
59% more capital invested
Capital invested by funds: $552K → $875K (+$323K)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$168K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$58.2K |
| 3 |
VF
Virtu Financial
New York
|
+$56.2K |
| 4 |
Two Sigma Investments
New York
|
+$42.7K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$8.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$127K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $310K | – | – | – |
|
|
2
Goldman Sachs
New York
| $166K | +$168K | +173 | New |
|
|
3
Renaissance Technologies
New York
| $90K | -$127K | -131 | -58% |
|
4
Bank of New York Mellon
New York
| $79K | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $58K | +$58.2K | +60 | New |
|
|
VF
6
Virtu Financial
New York
| $56K | +$56.2K | +58 | New |
|
|
7
Two Sigma Investments
New York
| $42K | +$42.7K | +44 | New |
|
8
Vanguard Group
Malvern,
Pennsylvania
| $39K | – | – | – |
|
9
Acadian Asset Management
Boston,
Massachusetts
| $23K | – | – | – |
|
|
10
Osaic Holdings
Scottsdale,
Arizona
| $9K | +$8.73K | +9 | New |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $3K | +$2.91K | +3 | New |
|
|
FP
12
Financial Perspectives
Minneapolis,
Minnesota
| $3 | – | – | – |
|
PSTV Hedge Fund Activity: Q3 2020 in Review
11 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q3 2020, worth a combined $875K — up 59% from $552K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PSTV positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $168K. The largest seller was Renaissance Technologies, cutting an estimated $127K.
- 11 institutional investors held Plus Therapeutics (PSTV) as of Q3 2020, up from 5 in Q2 2020.
- Funds reported $875K of Plus Therapeutics stock for Q3 2020, up 59% quarter-over-quarter.
- 6 funds opened new Plus Therapeutics positions in Q3 2020 and 0 closed out, a net change of +6 holders.
- The largest Plus Therapeutics buyer in Q3 2020 was Goldman Sachs, an estimated $168K added.
- The largest Plus Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $127K sold.
Based on aggregated 13F filings for Q3 2020.